Cargando…
Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire
BACKGROUND: Studies indicate that responses to HIV-2 treatment regimens are worse than responses to HIV-1 regimens during the first 12 months of treatment, but longer-term treatment responses are poorly described. We utilized data from Côte d’Ivoire’s RETRO-CI laboratory to examine long-term respons...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069012/ https://www.ncbi.nlm.nih.gov/pubmed/32164565 http://dx.doi.org/10.1186/s12879-020-4927-x |
_version_ | 1783505692616818688 |
---|---|
author | Minchella, Peter A. Adjé-Touré, Christiane Zhang, Guoqing Tehe, Andre Hedje, Judith Rottinghaus, Erin R. Kohemun, Natacha Aka, Micheline Diallo, Karidia Ouedraogo, G. Laissa De Cock, Kevin M. Nkengasong, John N |
author_facet | Minchella, Peter A. Adjé-Touré, Christiane Zhang, Guoqing Tehe, Andre Hedje, Judith Rottinghaus, Erin R. Kohemun, Natacha Aka, Micheline Diallo, Karidia Ouedraogo, G. Laissa De Cock, Kevin M. Nkengasong, John N |
author_sort | Minchella, Peter A. |
collection | PubMed |
description | BACKGROUND: Studies indicate that responses to HIV-2 treatment regimens are worse than responses to HIV-1 regimens during the first 12 months of treatment, but longer-term treatment responses are poorly described. We utilized data from Côte d’Ivoire’s RETRO-CI laboratory to examine long-term responses to HIV-2 treatment. METHODS: Adult (≥15 years) patients with baseline CD4 counts < 500 cells/μl that initiated treatment at one of two HIV treatment centers in Abidjan, Côte d’Ivoire between 1998 and 2004 were included in this retrospective cohort study. Patients were stratified by baseline CD4 counts and survival analyses were employed to examine the relationship between HIV type and time to achieving CD4 ≥ 500 cells/μl during follow up. RESULTS: Among 3487 patients, median follow-up time was 4 years and 57% had documented ART regimens for > 75% of their recorded visits. Kaplan-Meier estimates for achievement of CD4 ≥ 500 cells/μl after 6 years of follow-up for patients in the lower CD4 strata (< 200 cells/μl) were 40% (HIV-1), 31% (HIV-dual), and 17% (HIV-2) (log-rank p < 0.001). Cox Regression indicated that HIV-1 was significantly associated with achievement of CD4 ≥ 500 cells/μl during follow-up, compared to HIV-2. CONCLUSIONS: Sub-optimal responses to long-term HIV-2 treatment underscore the need for more research into improved and/or new treatment options for patients with HIV-2. In many West African countries, effective treatment of both HIV-1 and HIV-2 will be essential in the effort to reach epidemic control. |
format | Online Article Text |
id | pubmed-7069012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70690122020-03-18 Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire Minchella, Peter A. Adjé-Touré, Christiane Zhang, Guoqing Tehe, Andre Hedje, Judith Rottinghaus, Erin R. Kohemun, Natacha Aka, Micheline Diallo, Karidia Ouedraogo, G. Laissa De Cock, Kevin M. Nkengasong, John N BMC Infect Dis Research Article BACKGROUND: Studies indicate that responses to HIV-2 treatment regimens are worse than responses to HIV-1 regimens during the first 12 months of treatment, but longer-term treatment responses are poorly described. We utilized data from Côte d’Ivoire’s RETRO-CI laboratory to examine long-term responses to HIV-2 treatment. METHODS: Adult (≥15 years) patients with baseline CD4 counts < 500 cells/μl that initiated treatment at one of two HIV treatment centers in Abidjan, Côte d’Ivoire between 1998 and 2004 were included in this retrospective cohort study. Patients were stratified by baseline CD4 counts and survival analyses were employed to examine the relationship between HIV type and time to achieving CD4 ≥ 500 cells/μl during follow up. RESULTS: Among 3487 patients, median follow-up time was 4 years and 57% had documented ART regimens for > 75% of their recorded visits. Kaplan-Meier estimates for achievement of CD4 ≥ 500 cells/μl after 6 years of follow-up for patients in the lower CD4 strata (< 200 cells/μl) were 40% (HIV-1), 31% (HIV-dual), and 17% (HIV-2) (log-rank p < 0.001). Cox Regression indicated that HIV-1 was significantly associated with achievement of CD4 ≥ 500 cells/μl during follow-up, compared to HIV-2. CONCLUSIONS: Sub-optimal responses to long-term HIV-2 treatment underscore the need for more research into improved and/or new treatment options for patients with HIV-2. In many West African countries, effective treatment of both HIV-1 and HIV-2 will be essential in the effort to reach epidemic control. BioMed Central 2020-03-12 /pmc/articles/PMC7069012/ /pubmed/32164565 http://dx.doi.org/10.1186/s12879-020-4927-x Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Minchella, Peter A. Adjé-Touré, Christiane Zhang, Guoqing Tehe, Andre Hedje, Judith Rottinghaus, Erin R. Kohemun, Natacha Aka, Micheline Diallo, Karidia Ouedraogo, G. Laissa De Cock, Kevin M. Nkengasong, John N Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire |
title | Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire |
title_full | Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire |
title_fullStr | Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire |
title_full_unstemmed | Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire |
title_short | Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire |
title_sort | long-term immunological responses to treatment among hiv-2 patients in côte d’ivoire |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069012/ https://www.ncbi.nlm.nih.gov/pubmed/32164565 http://dx.doi.org/10.1186/s12879-020-4927-x |
work_keys_str_mv | AT minchellapetera longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT adjetourechristiane longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT zhangguoqing longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT teheandre longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT hedjejudith longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT rottinghauserinr longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT kohemunnatacha longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT akamicheline longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT diallokaridia longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT ouedraogoglaissa longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT decockkevinm longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire AT nkengasongjohnn longtermimmunologicalresponsestotreatmentamonghiv2patientsincotedivoire |